{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+IB&page=6", "query": { "condition": "Phase IB", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 1612, "total_pages": 162, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+IB&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+IB&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-05T11:52:53.029Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02055820", "title": "A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 267, "start_date": "2013-11-17", "completion_date": "2019-06-28", "has_results": true, "last_update_posted_date": "2020-06-11", "last_synced_at": "2026-11-05T11:52:53.029Z", "location_count": 9, "location_summary": "Fullerton, California • Los Angeles, California • Santa Maria, California + 6 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Maria", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02055820" }, { "nct_id": "NCT04431635", "title": "Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Indolent Lymphoma" ], "interventions": [ { "name": "Copanlisib", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2020-06-15", "completion_date": "2023-11-14", "has_results": false, "last_update_posted_date": "2024-09-27", "last_synced_at": "2026-11-05T11:52:53.029Z", "location_count": 5, "location_summary": "Chicago, Illinois • Ann Arbor, Michigan • Omaha, Nebraska + 1 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04431635" }, { "nct_id": "NCT03345420", "title": "Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ductal Breast Carcinoma In Situ", "Invasive Breast Carcinoma", "Stage 0 Breast Cancer", "Stage I Breast Cancer", "Stage IA Breast Cancer", "Stage IB Breast Cancer", "Stage II Breast Cancer", "Stage IIA Breast Cancer", "Stage IIB Breast Cancer" ], "interventions": [ { "name": "Hypofractionated Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 102, "start_date": "2017-12-12", "completion_date": "2025-06-26", "has_results": true, "last_update_posted_date": "2025-12-30", "last_synced_at": "2026-11-05T11:52:53.029Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03345420" }, { "nct_id": "NCT01362374", "title": "Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "5-FU", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 122, "start_date": "2011-07-11", "completion_date": "2020-10-16", "has_results": false, "last_update_posted_date": "2022-01-12", "last_synced_at": "2026-11-05T11:52:53.029Z", "location_count": 7, "location_summary": "San Francisco, California • Sarasota, Florida • Boston, Massachusetts + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT01362374" }, { "nct_id": "NCT00567879", "title": "A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Panobinostat", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 56, "start_date": "2008-04", "completion_date": "2011-05", "has_results": true, "last_update_posted_date": "2016-05-09", "last_synced_at": "2026-11-05T11:52:53.029Z", "location_count": 7, "location_summary": "Los Angeles, California • Aurora, Colorado • Norwalk, Connecticut + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Norwalk", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00567879" }, { "nct_id": "NCT01011010", "title": "Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Liver Cancer" ], "interventions": [ { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "mitomycin C", "type": "DRUG" }, { "name": "sorafenib tosylate", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 11, "start_date": "2009-07-22", "completion_date": "2017-09-29", "has_results": false, "last_update_posted_date": "2018-01-05", "last_synced_at": "2026-11-05T11:52:53.029Z", "location_count": 2, "location_summary": "Chapel Hill, North Carolina • Winston-Salem, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01011010" }, { "nct_id": "NCT04927559", "title": "Health Literacy in Understanding Radiation Therapy Information in Patients Undergoing Definitive Radiation Therapy", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage IA Breast Cancer AJCC v8", "Anatomic Stage IB Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage IIA Breast Cancer AJCC v8", "Anatomic Stage IIB Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Prognostic Stage I Breast Cancer AJCC v8", "Prognostic Stage IA Breast Cancer AJCC v8", "Prognostic Stage IB Breast Cancer AJCC v8", "Prognostic Stage II Breast Cancer AJCC v8", "Prognostic Stage IIA Breast Cancer AJCC v8", "Prognostic Stage IIB Breast Cancer AJCC v8", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Stage I Prostate Cancer AJCC v8", "Stage II Prostate Cancer AJCC v8", "Stage IIA Prostate Cancer AJCC v8", "Stage IIB Prostate Cancer AJCC v8", "Stage IIC Prostate Cancer AJCC v8", "Stage III Prostate Cancer AJCC v8", "Stage IIIA Prostate Cancer AJCC v8", "Stage IIIB Prostate Cancer AJCC v8", "Stage IIIC Prostate Cancer AJCC v8", "Stage IVA Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2020-12-18", "completion_date": "2024-04-23", "has_results": false, "last_update_posted_date": "2024-04-29", "last_synced_at": "2026-11-05T11:52:53.029Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04927559" }, { "nct_id": "NCT04140526", "title": "Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer", "Advanced Solid Tumor", "Metastatic Melanoma", "Metastatic Head and Neck Carcinoma", "Metastatic Renal Cell Carcinoma", "Metastatic Colorectal Cancer", "Sarcomas", "Metastatic Prostate Cancer", "Ovarian Cancer", "Small Cell Lung Cancer", "Metastatic Breast Cancer", "Pancreas Cancer", "Gastric Cancer", "Esophageal Cancer", "Gastroesophageal Junction Adenocarcinoma", "Cervical Cancer", "Adenoid Cystic Carcinoma", "Salivary Gland Cancer", "Urothelial Carcinoma" ], "interventions": [ { "name": "ONC-392", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OncoC4, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 733, "start_date": "2020-09-16", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-11-05T11:52:53.029Z", "location_count": 33, "location_summary": "Springdale, Arkansas • Davis, California • Downey, California + 27 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Davis", "state": "California" }, { "city": "Downey", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04140526" }, { "nct_id": "NCT04999826", "title": "Multiscale Omics for the Development of a Cohort Database and Study Platform in Breast Cancer Survivors", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Anatomic Stage 0 Breast Cancer AJCC v8", "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage IA Breast Cancer AJCC v8", "Anatomic Stage IB Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage IIA Breast Cancer AJCC v8", "Anatomic Stage IIB Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Prognostic Stage 0 Breast Cancer AJCC v8", "Prognostic Stage I Breast Cancer AJCC v8", "Prognostic Stage IA Breast Cancer AJCC v8", "Prognostic Stage IB Breast Cancer AJCC v8", "Prognostic Stage II Breast Cancer AJCC v8", "Prognostic Stage IIA Breast Cancer AJCC v8", "Prognostic Stage IIB Breast Cancer AJCC v8", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "FEMALE", "summary": "18 Years to 75 Years · Female only" }, "enrollment_count": 105, "start_date": "2021-04-01", "completion_date": "2022-12-30", "has_results": false, "last_update_posted_date": "2025-12-30", "last_synced_at": "2026-11-05T11:52:53.029Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04999826" }, { "nct_id": "NCT02416466", "title": "CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Liver Metastases" ], "interventions": [ { "name": "anti-CEA CAR-T cells", "type": "BIOLOGICAL" }, { "name": "Sir-Spheres", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DEVICE" ], "sponsor": "Roger Williams Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2015-04", "completion_date": "2018-06", "has_results": false, "last_update_posted_date": "2019-03-26", "last_synced_at": "2026-11-05T11:52:53.029Z", "location_count": 1, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT02416466" } ] }